USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.*
“USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
1. Offer available from December 25 2014 for a limited time only in Sydney and participating regions.
2. Orders already confirmed cannot avail of the offer. It is only open to new inquiries from 25/12/2014. Quotes prior to the sale can be requoted upon request to take up the offer.
3. Not valid with any other discounts or interest free offer.
4. Installation and accessories do not form part of the offer and will be charged as per the normal retail prices.
5. Discount is off Apollo’s normal selling prices.
6. The ranges applicable are as follows:
*20% Off
Panel Glides
Cellular Blinds
Viewline Shades
* 25% Off
Roller Blinds
Fabric Verticals
Venetians
Roller Shutters
Roman Blinds
* 30% Off
Awnings
* 35% Off
Shicane Verticals
*40% Off
All Louvre Shutters
http://apolloblinds.com.au/specials-2/
Ruckus Wireless™ today said that the first large-scale, high-speed public Wi-Fi network that was deployed at this year’s Sundance Film Festival offloaded terabytes of data from local cellular networks, delivering high capacity broadband access to Sundance moviegoers.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/ruckuswireless/48551/
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
The loss of energy through windows can account for up to 20 percent of a home’s total heating and cooling costs. With a scorching summer drawing to a close and heating costs expected to rise as high as 30 percent this year, many Americans are already looking for ways to curtail energy costs this winter. New Levolor® Accordia™ Cellular Shades offer the most energy efficient window solution available, saving homeowners up to $180 on their annual energy bills. With more than 200 fabrics to choose from, including exclusive woven textures, and ingenious options such as cordless, homeowners will never have to sacrifice style for efficiency.
To view Multimedia News Release, go to http://www.multivu.com/players/English/45407-Levolor-Accordia-Cellular-Shades/
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
From remote mountains to rural country roads and even up to 200 miles off the coast of the United States, consumers can now enjoy the freedom and flexibility to stay connected with the availability of the TerreStar™ GENUS™, the world’s first integrated cellular-satellite smartphone. Offered by mobile communications provider, TerreStar Networks Inc. (“TerreStar”), the GENUS ensures today’s active lifestyle consumer, from the extreme outdoor adventurer and action sport enthusiast to the recreational boater, can stay connected even in remote locations or when the cellular network is down.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/terrestar/47306/
eTrak announces the release of their GPS+ line of consumer and commercial tracking products. GPS+ is eTrak’s patent pending technology that integrates the usage of WIFI, cellular triangulation and GPS to achieve the most accurate positioning possible, both indoors and out.
GPS+ delivers the most accurate location available in real time directly to a Smartphone, tablet or computer. eTrak products also contain geo-fencing capability which triggers notifications if the device goes beyond preset boundaries. Additionally, the notifications provide a map and address with the location of the device.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60966-etrak-powered-by-verizon-wireless-at-ctia-gps-plus-product-line
CBI Polymers Inc., the U.S.-based innovator of DeconGel® nuclear decontaminant, announced today the collaborative effort to remediate radiation from the campus of the Asahimachi Baptist Church and Little Lamb Kindergarten in Fukushima, Japan, in a project CBI Polymers calls “Restore Playtime.”
CBI Polymers donated its DeconGel® nuclear decontaminant and the manpower to apply the blue gel to the affected areas of the school. Once dry, the gel was peeled away, taking harmful radiation with it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cellular-bioengineering/46957/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
